| Name | Lincare Inc |
|---|---|
| Organization Name | Lincare Inc |
| Location | 2600 Millcork St, Ste B, Kalamazoo, Michigan 49001 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (269) 964-0030 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Applied Nanodetectors Ltd is developing a simple breathalyser that will give diabetics a non invasive method for monitoring their daily glucose levels and has the potential to replace the ‘prick test' methods used today.
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
Sleep for people over 55 often involves waking up several times during the night, not being able to get back to sleep and waking up earlier than desired in the morning.
Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
› Verified 6 days ago
| NPI Number | 1013221134 |
| Organization Name | LINCARE INC. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2600 B Millcork St, Kalamazoo, MI 49001 |
| Phone Number | 269-964-0030 |
News Archive
Applied Nanodetectors Ltd is developing a simple breathalyser that will give diabetics a non invasive method for monitoring their daily glucose levels and has the potential to replace the ‘prick test' methods used today.
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
Sleep for people over 55 often involves waking up several times during the night, not being able to get back to sleep and waking up earlier than desired in the morning.
Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
› Verified 6 days ago
| NPI Number | 1750455275 |
| Organization Name | LINCARE INC. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2600 Millcork St Ste B, Kalamazoo, MI 49001 |
| Phone Number | 269-345-2011 |
News Archive
Applied Nanodetectors Ltd is developing a simple breathalyser that will give diabetics a non invasive method for monitoring their daily glucose levels and has the potential to replace the ‘prick test' methods used today.
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
Sleep for people over 55 often involves waking up several times during the night, not being able to get back to sleep and waking up earlier than desired in the morning.
Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
› Verified 6 days ago
News Archive
Applied Nanodetectors Ltd is developing a simple breathalyser that will give diabetics a non invasive method for monitoring their daily glucose levels and has the potential to replace the ‘prick test' methods used today.
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
Sleep for people over 55 often involves waking up several times during the night, not being able to get back to sleep and waking up earlier than desired in the morning.
Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
› Verified 6 days ago
Carelinc Medical Equipment & Supply Type: DME Supplier - Oxygen Equipment & Supplies Location: 5125 Portage Rd, Kalamazoo, Michigan 49002 Phone: (269) 273-5500 | |
Cvs Pharmacy #16332 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5350 W Main St, Kalamazoo, Michigan 49009 Phone: (269) 349-6290 | |
Cvs Pharmacy #10548 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2600 W Michigan Ave, Kalamazoo, Michigan 49006 Phone: (269) 343-4232 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2600 Millcork St, Kalamazoo, Michigan 49001 Phone: (269) 964-0030 | |
Rite Aid Pharmacy #01478 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1032 E Cork St, Kalamazoo, Michigan 49001 Phone: (269) 344-0131 |